Kendall, Timothy J. http://orcid.org/0000-0002-4174-2786
Jimenez-Ramos, Maria http://orcid.org/0009-0000-8273-0805
Turner, Frances
Ramachandran, Prakash
Minnier, Jessica
McColgan, Michael D.
Alam, Masood
Ellis, Harriet
Dunbar, Donald R.
Kohnen, Gabriele
Konanahalli, Prakash
Oien, Karin A.
Bandiera, Lucia
Menolascina, Filippo
Juncker-Jensen, Anna
Alexander, Douglas
Mayor, Charlie http://orcid.org/0000-0003-4729-3536
Guha, Indra Neil http://orcid.org/0000-0002-6940-5861
Fallowfield, Jonathan A. http://orcid.org/0000-0002-5741-1471
Article History
Received: 12 April 2023
Accepted: 20 September 2023
First Online: 30 October 2023
Competing interests
: T.J.K. serves as a consultant for or has received speakers’ fees from Resolution Therapeutics, Clinnovate Health, Perspectum and Incyte Corporation. P.R. serves as a consultant for Merck and has received research grant funding from Genentech. J.A.F. serves as a consultant or advisory board member for Resolution Therapeutics, Kynos Therapeutics, Ipsen, Redx Pharma, River 2 Renal Corp., Stimuliver, Galecto Biotech, Global Clinical Trial Partners and Guidepoint and has received research grant funding from Intercept Pharmaceuticals and Genentech. A.J.-J. is an employee and stock owner at NeoGenomics. I.N.G. serves as an advisory board member for Resolution Therapeutics and has received research grant funding from Gilead Sciences. M.D.M. and D.R.D. have a controlling shareholder interest in Biodev Ltd. The remaining authors declare no competing interests.